Clinical Trials Logo

Filter by:
NCT ID: NCT04781907 Withdrawn - Clinical trials for Breast Reconstruction

Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction

Start date: June 2024
Phase: N/A
Study type: Interventional

This study is designed to evaluate the feasibility and safety of patient performed tissue expansions in two-stage alloplastic breast reconstruction with tissue expanders. The investigators hypothesize that a motivated patient who learns and demonstrates proper technique can safely perform tissue expansions at home, with no increase in complications or problems with reconstruction. 30 participants will be recruited for this study, 10 into a Home Expansion Group, and 20 into a Control Group.

NCT ID: NCT04781374 Withdrawn - Prostate Cancer Clinical Trials

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 21, 2021
Phase: Phase 2
Study type: Interventional

This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. - The names of the study drug involved in this study is neratinib.

NCT ID: NCT04778566 Withdrawn - Colorectal Cancer Clinical Trials

Evaluating the Cologuard Test for Use in Lynch Syndrome

Start date: November 2021
Phase:
Study type: Observational

This study is aiming to enroll 90 patients with genetically confirmed Lynch Syndrome (LS) from Geisinger's High Risk Colorectal Cancer Clinic (HRC). Upon enrollment in the study, a Cologuard test will be ordered and the results will be blinded until data analysis. Patients enrolled in the study will also undergo a colonoscopy as part of their routine HRC visit.

NCT ID: NCT04776980 Withdrawn - Clinical trials for Glioblastoma Multiforme

Multimodality MRI and Liquid Biopsy in GBM

Start date: June 2022
Phase: Early Phase 1
Study type: Interventional

Patients with a new diagnosis of high-grade glioma based on MRI, who are considered surgical candidates determined by neurosurgeons or patients with recurrent glioblastoma with the initial diagnosis of glioblastoma (histologic or molecular proof) and recommended for clinically surgical resection may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age. Ferumoxytol-enhanced MRI will be used to quantify tumor-associated macrophages. This is a non-therapeutic trial in that imaging will not be used to direct treatment decisions. The blood draw is being completed to evaluate cell-free circulating tumor DNA (cfDNA) and cell-free tumor DNA (ctDNA).

NCT ID: NCT04774484 Withdrawn - Clinical trials for End Stage Renal Disease

High-Intensity Interval Training and Regulatory T Cells

Start date: January 2023
Phase: N/A
Study type: Interventional

Regulatory T cells (Tregs) are a small population of T cells compromising of 1% to 5% of the total T cells in the body but they are playing a fundamental role in the maintenance of the immune homeostasis. These cells modulate the immune system by suppressing the effector activity and thus preventing autoimmune diseases and chronic inflammatory processes. Treg cell numbers have shown to increase with physical activity, and this increment has been directly correlated with exercise intensity. These results suggest that the increased Treg frequency may contribute to the beneficial effects of exercise on disorders associated with autoimmune disease or chronic low-grade inflammation such as atherosclerosis, diabetes mellitus, chronic kidney disease or cancer. The overall purpose of this study is to determine the influence High-intensity interval training (HIIT) on the frequency and quality of peripheral Treg cells.

NCT ID: NCT04771351 Withdrawn - Covid19 Clinical Trials

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

Start date: April 2021
Phase: Phase 2
Study type: Interventional

This is a placebo-controlled study to investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults with COVID-19.

NCT ID: NCT04770831 Withdrawn - Clinical trials for Brain and Nervous System

Patients Who Receive 131 I-MIBG

Start date: March 10, 2021
Phase:
Study type: Observational

This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.

NCT ID: NCT04770714 Withdrawn - Breast Cancer Clinical Trials

Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients

Start date: January 19, 2021
Phase: N/A
Study type: Interventional

In current clinical practice, women with biopsy proven breast cancer can be sent for breast magnetic resonance imaging (MRI) or contrast enhanced mammography (CEM) prior to surgery in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers. This study seeks to compare the global costs (based on actual reimbursement rates) of CEM/breast MRI, downstream imaging testing, and diagnostic procedures in women randomized to breast MRI versus CEM. Secondary goals are to compare patient preferences for CEM vs MRI and clinically relevant outcomes (e.g. conversion from lumpectormy to mastecomy).

NCT ID: NCT04770064 Withdrawn - Clinical trials for Osteoarthritis, Knee

Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

ROPE
Start date: June 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Symptomatic knee osteoarthritis (OA) is the most common joint disorder in the U.S. and a leading cause of disability. Increasing age, obesity, and previous injury increase the lifetime risk of knee OA, but these factors are also independently associated with increased cellular senescence. Senescent cells accumulate in many tissues and contribute to chronic pathologies, linked to the secretion of pro-inflammatory factors collectively known as the senescence-associated secretory phenotype. In OA, senescent cells promote production of cytokines, chemokines, and matrix-degrading enzymes involved in progressive cartilage breakdown. The senolytic supplement fisetin alters the inflammatory and catabolic cartilage responses, which may clinically lessen OA pain while also slowing progressive cartilage breakdown. The purpose of this double-blind, randomized clinical trial is to compare 2 fisetin dosing regimens versus placebo. Sixty patients with mild to moderate knee OA will be assessed at baseline and 3 months in an effort to: determine if 2 different fisetin dosing regimens lessen pain and functional impairment compared to placebo, compare progressive changes in senescent cell activity and biomarkers of cartilage degradation between different fisetin dosing regimens and placebo, and assess acceptability and feasibility of 2 fisetin dosing regimens.

NCT ID: NCT04768478 Withdrawn - Ankle Fractures Clinical Trials

CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effects of administering CBD to control post-operative pain in patients undergoing ankle fracture open reduction and internal fixation, tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair (open reduction internal fixation or intramedullary nail fixation), or tibial plateau open reduction and internal fixation. Secondly, the purpose is to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.